What is Atomwise?
Founded in 2012 and headquartered in California, Atomwise Inc. operates at the forefront of the digital health revolution. The company utilizes deep learning and neural networks to predict the efficacy of small molecules, effectively shortening the timeline for drug discovery and reducing the costs associated with traditional laboratory experimentation. By transforming the way pharmaceutical entities identify potential therapeutic candidates, Atomwise has established a robust market position as a key enabler for global drug development programs. Its platform is designed to handle complex molecular interactions, providing a scalable solution for the discovery of novel medicines across a wide range of disease areas.
How much funding has Atomwise raised?
Atomwise has raised a total of $221.6M across 7 funding rounds:
Unspecified
$225K
Other Financing Round
$120K
Angel/Seed
$6M
Series A
$45M
Series B
$123M
Grant
$2.3M
Series C
$45M
Unspecified (2013): $225K with participation from Grand Challenges Canada
Other Financing Round (2015): $120K led by David E. Weekly and Y Combinator
Angel/Seed (2015): $6M supported by AME Cloud Ventures, Data Collective, Draper Fisher Jurvetson, Khosla Ventures, and OS Fund
Series A (2018): $45M featuring Tencent, Baidu Ventures, Y Combinator, Khosla Ventures, Monsanto Growth Ventures, B Capital Group, and Data Collective
Series B (2020): $123M backed by Tencent, Y Combinator, DCVC, B Capital Group, Dolby Family Ventures, AME Cloud Ventures, Sanabil Investments, and BV
Grant (2020): $2.3M with participation from Bill & Melinda Gates Foundation
Series C (2024): $45M led by Khosla Ventures and B Capital Group
Key Investors in Atomwise
Tencent
Tencent is a global technology conglomerate that invests in innovation across digital platforms, cloud computing, and artificial intelligence to support developers and businesses.
Khosla Ventures
A prominent venture capital firm founded by Vinod Khosla, focusing on breakthrough technologies in AI, health, and enterprise sectors.
B Capital Group
A global venture capital firm that empowers entrepreneurs by investing in early and late-stage companies within the technology and healthcare sectors.
What's next for Atomwise?
With the recent injection of $45M, Atomwise is well-positioned to enhance its computational infrastructure and expand its collaborative partnerships with global pharmaceutical leaders. The strategic focus moving forward involves deepening the integration of its AI models with high-throughput screening data to further improve predictive accuracy. As the company matures, it is expected to prioritize the advancement of its internal pipeline while simultaneously scaling its enterprise-level service offerings. This trajectory suggests a long-term objective of becoming the industry standard for AI-powered molecular design, ultimately driving a paradigm shift in how the global healthcare sector approaches the development of life-saving treatments.
See full Atomwise company page
